welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)
WVE-210201 safety and tolerability profile supports Phase 2/3 clinical trial initiation in boys with DMD amenable to exon 51 skipping Delivery of interim efficacy data from ongoing open-label extension study expected in H2 2019 CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the safety and tolerability data from the WVE-210201 Phase 1 clinical trial in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping support initiation of a Phase 2/3 clinical trial. Based on results from four ascending dose cohorts in the Phase 1 trial and pending final analysis, Wave has selected a dose for its planned Phase 2/3 clinical trial of WVE-210201, which it intends to initiate in 2019. In parallel, the independent Safety Monitoring Committee of the Phase 1 clinical trial has endorsed moving forward with a higher dose of WVE-210201 to be studied in a fifth cohort. Wave plans to present the results from the WVE-210201 Phase 1 clinical trial, as well as details of the Phase 2/3 study design, at upcoming scientific meetings.
rareRelated
-
Insurers battle families over costly drug for fatal diseaseNolan and Jack Willis, twins from upstat...
-
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017We issued an updated research report on ...
-
Open Label Study of GSK2402968 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to explore ...
-
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
-
FDA paves way for clinical trials of Sarepta’s Duchenne MD therapy SRP-5051The U.S. Food and Drug Administration ha...
-
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patie...Sarepta Therapeutics, Inc., a leader in ...
-
Pharmacokinetic Properties of Chronic Administration of Eteplirsen in the Treatment of Boys with Duchenne Muscular D...Objective: The objective of this analys...